ClinicalTrials.gg
CompletedNCT05547503Updated Oct 21, 2025

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

A Phase 1 interventional study of AFA-281 in Pain, Neuropathic and Pain, Inflammatory, sponsored by Afasci Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Afasci Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.

Enrollment
98th of 261
64 · median 40
Started
2023
with 16 others
Phase 1
20 of 291
6 open now
Registered
222nd of 291
by date

Among the 291 studies in Neuralgia with a site in United States, this one is the 98th largest by enrollment of the 261 interventional ones that give a count, is one of 17 that started in 2023, is one of 20 in phase 1, and was the 222nd registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Neuralgia with a site in United States, or all of them as a file.
02

Study summary

Phase I Part 1 (single ascending dose):

Double-blind dosing will occur in healthy volunteers in 4 cohorts of 8 subjects each. Six subjects in each cohort will be randomized to receive AFA-281 and 2 subjects will be randomized to receive the matching placebo. At the end of the Part 1 study is to evaluate the safety and tolerability of AFA-281. Following completion of each cohort, bioanalytical analyses will be conducted to evaluate the pharmacokinetic profile.

Phase I Part 2 (multiple dose for 14 days):

Pending the results from Part 1, healthy volunteers will be administered AFA-281 for 14 to 21 consecutive days in 3 cohorts. At scheduled intervals after dosing, and at the end of the cohort's study period to evaluate the safety and tolerability and the pharmacokinetic profile of AFA-281.

Read the detailed description

Phase I Part 1 (single ascending dose):

Healthy volunteers will be admitted to the clinical research unit on Day -1. There will be five cohorts with 8 subjects per cohort. Six subjects per cohort will receive AFA-281 at one of 4 doses and 2 will receive placebo. Oral capsules will be administered on the morning of Day 1, following a 10-hour fast. Blood draws for assessment of Pharmacokinetic parameters will occur 0.2-1 hr pre-dose and at 0.5-, 1-, 2-, 3-, 4-, 8-, 10, 12-, 16-, 24-, 36-, 48-hr, and up to 72-hr post-dose. Vital signs will be collected at scheduled times following dosing. A 12-lead ECG will be obtained pre-dose and scheduled at 2, 4, 8, 24 hr, and 3- or 4 days post- dose. Various clinical laboratory tests will be drawn on Day -1, within 1 hr prior to dosing, and at scheduled timepoints after dosing while the volunteer is housed in the research center. Subjects of Cohorts 1 - 3 will be released following completion of blood draws and safety assessments up to 48 hours and Cohorts 4 and 5 subjects will return for 72-hour blood draws and Day 4 ECG and safety assessment.

Phase I Part 2 (multiple ascending doses - 14 days):

After assessment of the safety data from the single dose Phase I Part 1, healthy volunteers will be randomized into 3 cohorts with 8 subjects per cohort. Five subjects per cohort will receive AFA-281 and 3 will receive placebo. Oral capsules will be administered in dose titration and split daily dose in fours time daily (QID) for 14 - 21 consecutive days. Routine clinical monitoring will occur as in Part 1. Baseline physical examination, vital signs, clinical lab tests, and ECGs will be performed prior to dosing, at scheduled intervals after dosing, and at the end of the cohort's study period to evaluate the safety and tolerability, and the pharmacokinetic profile of AFA-281. Reports of potential adverse events will be elicited, and vital signs and 12-lead ECG will be measured in a similar manner to Part 1. Similarly, clinical laboratory tests will be drawn prior to and after dosing.

03

Conditions studied

  • Pain, Neuropathic
  • Pain, Inflammatory
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be in good general health with no significant medical history and have no abnormalities on physical examination at screening and/or before administration of the initial dose of study drug.

    • Participants must have a (BMI) between 18.0 and 30.0 kg/m2 inclusive.
    • Participants must have clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the Investigator or delegate.
    • Participants must have an without clinically significant pathologic abnormalities.

Exclusion criteria

Exclusion Criteria:

  • Participants with significant medical history or abnormalities
  • Participants with clinically significantly pathologic abnormalities
  • Participants with abnormalities
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Placebo comparator
    Placebo Control

    Double blind placebo control

    Drug: AFA-281

  • Experimental
    AFA-281

    Part 1: AFA-281 administered as an oral capsule at 5 dose levels for one day. Part 2: AFA-281 administered as an oral capsule at 3 dose levels twice daily for 14 consecutive days. Doses will be determined after completion of Part 1.

    Drug: AFA-281

Interventions

  • Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)

06

What researchers measure

Primary outcomes

  1. Treatment-Related Adverse Events

    Number of participants with treatment-related adverse events will be assessed using CTCAE v5.0

    Time frame: Predose and Up to 72 hours after dose

  2. Heart rate

    Heart rate as one of vital signs will be measured

    Time frame: Predose and Up to 72 hours after dose

  3. Body temperature

    Body temperature (0C) as one of vital signs will be measured

    Time frame: Predose and Up to 72 hours after dose

  4. Blood Pressure

    Blood pressure as one of vital signs will be measured

    Time frame: Predose and Up to 72 hours after dose

  5. Electrocardiogram (ECG)

    Triplicate 12-lead ECG will be measured to evaluate electrical activity of the heart

    Time frame: Pre-dose and up to 72 hours after dose

  6. Blood chemistry

    Blood chemistry parameters will be measured

    Time frame: Pre-dose and up to 72 hours after dose

  7. Hematology

    Hematology parameters will be measured

    Time frame: Pre-dose and up to 72 hours after dose

  8. Coagulation

    Coagulation parameters (PT/INR, PTT) will be measured

    Time frame: Pre-dose and up to 72 hours after dose

  9. Urinalysis

    Urinalysis parameters will be measured using dipstick and microscopic examination.

    Time frame: Pre-dose and up to 72 hours after dose

  10. Blood maximum plasma concentration (Cmax) of the study drug

    Pharmacokinetics parameter Cmax will be measured to assess drug exposure levels in blood

    Time frame: Pre-dose and up to 72 hours after dose

  11. Blood study drug half-life (t1/2)

    Pharmacokinetics parameter t1/2 will be measured to evaluate drug half-life in the blood

    Time frame: Pre-dose and up to 72 hours after dose

  12. Area under the plasma concentration versus time curve (AUC) of the study drug

    Pharmacokinetics parameter AUC will be measured

    Time frame: Pre-dose and up to 72 hours after dose

Secondary outcomes

  1. A dose and exposure relationship

    Doses of study drug and blood exposure levels will be analyzed to determine dose proportionality.

    Time frame: Pre-dose and up to 72 hours after dose

  2. Tmax of the study drug (parent compound) in blood

    Pharmacokinetics parameter Time at which Cmax of the study drug appeared will be determined.

    Time frame: Up to 72 hours after dose

  3. Plasma Concentration (Cmax) of the major metabolite in blood

    Pharmacokinetics parameter Cmax of a major metabolite will be measured.

    Time frame: Up to 72 hours after dose

  4. Area under the plasma concentration versus time curve (AUC) of the major metabolite in blood

    Pharmacokinetics parameter AUC of a major metabolite will be measured.

    Time frame: Up to 72 hours after dose

  5. The major metabolite half-life (t1/2) in blood

    Pharmacokinetics parameter t1/2 of a major metabolite will be measured.

    Time frame: Up to 72 hours after dose

07

Study locations

1 site
  • CenExcel CNS
    Los Alamitos, California 90720, United States
08

References and documents

Individual participant data

Plan to share: Yes — One year after completion of the study and 6 months after publication

Supporting information: Statistical analysis plan, Informed consent form

Time frame: One year after completion of the study and 6 months after publication

Access criteria: To be added

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Dec 2024, 19 months.

Of 36 phase 1 interventional studies under Neuralgia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 21, 2022
StartActual
Apr 11, 2023
Primary completionActual
Dec 4, 2024
CompletionActual
May 14, 2025
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05547503
Lead sponsor
Afasci Inc
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
Sep 21, 2022
Start date
Apr 11, 2023
Primary completion
Dec 4, 2024
Completion
May 14, 2025
Last update
Oct 21, 2025

Study contacts

Xinmin Xie, MD, PhD
study chair · Afasci Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AFA-281

Start the discussion